



Includes  
1-2-1  
partnering  
meetings

# Infectious Diseases

Networking event: 22nd October 2008, BMA House, London

## Innovative technologies for detection, treatment and prevention

### Benefits of attending:

- **A UNIQUE OPPORTUNITY** to identify technology partners through one-to-one meetings
- **LEARN ABOUT** developing an 'early warning system' with an Active Surveillance of Pathogens microarray
- **DISCOVER** the newest advances in anti-sera for bio defence purposes
- **EVALUATE** cutting-edge technology in antiviral nanoparticle materials
- **FIND OUT ABOUT** innovation in adjuvanted vaccines for influenza

Supported by



### Speakers include:

Dr Tim Brooks  
**Health Protection Agency**

Paul Gascoigne  
**Smiths Detection**

Dr Frederick Vogel  
**sanofi pasteur**

Dr Claire Turner  
**Cranfield University**

Professor Brendan Wren  
**London School of  
Hygiene and Tropical  
Medicine**

For further information, contact [s.ohene@LTNetwork.org](mailto:s.ohene@LTNetwork.org); 0870 730 8656  
[www.LTNetwork.org](http://www.LTNetwork.org)

© LTN 2008 programme may be subject to change

# Infectious Diseases

## Innovative technologies for detection, treatment and prevention

According to the US Centers for Disease Control and Prevention, infectious diseases accounted for 26% of all deaths worldwide in 2002. The increase in global human travel, coupled with the emergence of new diseases and the growth in antibiotic-resistant strains means that infectious diseases remain a significant threat. The deliberate introduction of biological agents for terrorist purposes is another cause for concern. This conference will start with a look at the latest technological developments in the detection of infectious diseases before going on to address the most recent technology advances in their treatment and prevention.

08.45 Registration

09.30 **Introduction to London Technology Network**  
**Jolyon White**, Technology Consultant, **London Technology Network**

10.25 **Panel discussion**

10.50 **Networking break with academic poster and partnering sessions**

### Session 1: Detection Technologies

09.40 **Can you smell TB?**

- Developing a sensor to detect specific TB volatile compounds
- Using mass spectrometric methods to find TB biomarkers
- Combining these approaches to offer the possibility of a “smelling” diagnostic TB test

**Dr Claire Turner**, Lecturer, Volatiles Research, **Cranfield University**

09.55 **Development of an Active Surveillance of Pathogens microarray (ASP array)**

- Examining how the ASP array technology can be used as an ‘early warning system’ to detect emerging pathogens
- Improving the rapidity of ASP array identification
- Examining the possible applications of the ASP array

**Brendan Wren**, Professor of Microbial Pathogenesis, **London School of Hygiene and Tropical Medicine**

10.10 **Designing detection technology for challenging environments**

- An overview of the logistical problems to be considered with detection of biological agents ‘in the field’
- New developments in pcr-based technologie
- Establishing where new technology is required, and the potential for collaboration between industry and academia

**Paul Gascoigne**, Biotechnologist, **Smiths Detection**

### Session 2: Treatment Technologies

11.30 **New diagnostic assays to improve HIV therapy**

- Examining the correlation between HIV resistance and viral fitness
- The importance of HIV coreceptor typing
- Evaluating novel antiretrovirals, including cellular targets

**Dr Matthias Dittmar**, Senior Lecturer in Infection, Centre for Infectious Diseases, **Barts and The London School of Medicine and Dentistry**

11.45 **Bacteriophage therapy for antibiotic-resistant *Pseudomonas aeruginosa* infections**

- An overview of the development of bacteriophage therapy for resistant *Pseudomonas aeruginosa*
- Assessing the results of the first phase 2 trials of bacteriophage therapy, targeting resistant *Pseudomonas aeruginosa* infection of the ear
- Using bacteriophage therapy to enhance the efficacy of conventional antibiotics
- Evaluating other new technologies in bacteriophage therapy and the opportunities for collaboration between academia and industry

**David Harper**, Chief Scientific Officer, **Biocontrol Ltd**

### SPONSORSHIP

This unique event will be an excellent opportunity to initiate new relationships through tailored networking and a showcase of the latest academic research. LTN offers a range of sponsorship packages to enhance your brand, for further information contact Kate Ray on **0870 730 8682** or **k.ray@LTNetwork.org**

For further information, contact **s.ohene@LTNetwork.org**

© LTN 2008 programme may be subject to change

- 12.00 **Anti-sera for the 21st Century**
- Evaluating the limitations to current anti-sera technologies
  - Examples of successful application of this technology: development of anti-sera for botulinum, smallpox and the side effects of smallpox vaccine
  - Key areas where new technology developments are required, and the importance of design for manufacture

**Dr Tim Brooks**, Head of Novel and Dangerous Pathogens Group, Centre for Emergency Preparedness and Response, **Health Protection Agency**

12.15 **Panel discussion**

12.45 **Lunch with academic poster and partnering sessions**

14.00 **Spotlight on innovative technologies in the industry sector**

During this session, a selected number of companies will have the opportunity to give a short presentation on their latest innovation. If you are interested in showcasing your work, please contact **Kate Ray** at [k.ray@LTNetwork.org](mailto:k.ray@LTNetwork.org) or on **0870 730 8682**

**Session 3: Prevention Technologies**

14.30 **Combating the spread of infectious diseases with AVNP materials**

- An overview of antiviral nanoparticle materials technology and the challenges that it addresses
- Evaluating the impact of this innovation on the area of prevention technologies as a whole
- Establishing where further technology developments are required and the possibilities for collaboration between industry and academia

**Dr Peter Allan**, Wolfson Centre, **Brunel University**

14.45 **Innovation in influenza vaccine development: adjuvants and pandemic preparedness**

- Overview of sanofi pasteur's pandemic influenza vaccine activities
- Use of immunologic adjuvants for pandemic influenza vaccines
- Results from sanofi pasteur's preclinical and clinical studies of adjuvanted H5N1 influenza vaccines

**Dr Frederick R Vogel**, Project Director R&D, **sanofi pasteur**

15.00 **Networking break with academic poster and partnering sessions**

15.30 **The latest research into development of a vaccine for Hepatitis C**

- Working on a novel approach to the development of a Hep C vaccine, in collaboration with Okairos
- HCV, immunity and the rationale behind this approach

**Dr Ellie Barnes**, Institute of Emerging Infections, **University of Oxford**

15.45 **Meeting the challenges of developing a modern biodefence vaccine**

- Identifying the challenges to developing biodefence vaccines
- The latest technology developments for plague/anthrax vaccines
- The implications of these developments for vaccine technology as a whole
- Establishing where new technology is required and potential opportunities for collaboration between industry and academia

**Dr Matthew Duchars**, Chief Scientific Officer, **PharmAthene**

16.00 **Panel discussion**

16.20 **End of conference followed by tea and further one-to-one partnership meetings**



The **Emerging Medical Technologies** Group was founded in 2007, and brings together professionals from industry, academia and government across the Greater South-East of England to stimulate knowledge exchange through networking events, newsletters and technology matchmaking services.

The Emerging Medical Technologies Group helps you to:

- Improve your own competitiveness through access to innovative technologies
- Attain better knowledge to improve company processes
- Promote your own organisation to a fundamental market
- Network with other like-minded individuals working across various relevant sectors
- Access new technology and business markets from across Europe
- Facilitate information sharing on new technologies, innovation policy, funding and other issues
- Support technology transfer between companies and academia

To find out more or to join the Group, contact **Natalie** at [n.tamiollo@LTNetwork.org](mailto:n.tamiollo@LTNetwork.org) or **+44 (0)870 730 8683**.

*The Emerging Medical Technologies Group is a project of LTN*

**All events are by INVITATION ONLY**

For further information, contact [s.ohene@LTNetwork.org](mailto:s.ohene@LTNetwork.org)

© LTN 2008 programme may be subject to change

# Registration

<b>Payment:</b>	<b>Early bird special</b> (until 24 September 2008)	<b>£150.00 (+ VAT = £176.25)</b>	(Concessionary Price 1)
	<b>Commercial</b>	<b>£200.00 (+ VAT = £235.00)</b>	(Standard)
	<b>Academic* and SME**</b>	<b>£75.00 (+ VAT = £88.12)</b>	(Concessionary Price 2)

\* Academic rate is extended to full-time employees of government, universities and university-affiliated hospitals only.

\*\* SME (Small and Medium Enterprises) rate is available to companies with up to 250 employees.

Costs for the conference are shown above. The fees are all exclusive of VAT (17.5%). **All payments must be received prior to the conference and should be made within 14 days of receiving a provisional place.** Attendance will be confirmed upon receipt of payment. Prices include reception, lunch, refreshments and delegate documentation. All LTN events are by INVITATION ONLY to ensure that the quality of interaction is maintained. To apply for an invitation, and to find out about different payment methods, please email **Sheila Ohene** at [s.ohene@ltnetwork.org](mailto:s.ohene@ltnetwork.org). **Cancellations must be made at least 5 working days before the event.**

## Testimonials

*"I met a vital contact at the event which would have been highly unlikely to have met them anywhere else"*

**Dr Mark Maconochie, University of Sussex**

*"It's never easy trying to get hold of the right people – and there were a number of companies at the event that I have been trying to meet for a while. The European contacts that were brought across were excellent. I have a number of interesting opportunities coming up as a result"* **Tak Ishikawa, Ilika Technologies Limited**

This event will take place at  
**BMA House, Tavistock Square, London, WC1H 9JP**

## How to get there

This event will take place at BMA House, Tavistock Square, London, WC1H 9JP, Tel: 020 7383 6963/6692

For a more detailed view, please go to: <http://www.bmahouse.org.uk/bmahouse.nsf/Content/WhereToFindUs>



BMA House is easily accessible by public transport.

The nearest Underground stations are Euston (Northern and Victoria lines), Russell Square (Piccadilly line) and Euston Square (Circle, Metropolitan and Hammersmith and City lines)

The closest main line train stations are Euston and King's Cross St Pancras which are less than 10 minutes' walk away.

For further information, contact: [s.ohene@LTNetwork.org](mailto:s.ohene@LTNetwork.org)

© LTN 2008 programme may be subject to change